retatrutide phase 2 nejm weight loss 48 weeks triple agonist vs. Ozempic: The That May Change Everything., Semaglutide hits one receptor. Retatrutide hits three., That difference may be the biggest leap in metabolic medicine since , Great news again!!! A phase

A year of transformation: The global pharmaceutical market in 2025 Beyond these macroenvironmental shifts shaping the industry, the global prescription medicine market delivered strong underlying performance in 2025

Rotator cuff tendons can have partial tears or complete ruptures

The pure patent-maximization strategy that drove pharmaceutical IP management for the previous two decades is no longer automatically optimal in an IRA environment

Injectable GLP-1s may remain the preferred option for patients with severe obesity or related conditions such as cardiovascular or liver disease, while oral therapies appear to be drawing in a different set of users